Majid, H.; Puzik, A.; Maier, T.; Merk, R.; Bartel, A.; Mueller, H.-C.; Burckhardt, B.B.
Formulation Development of Sublingual Cyclobenzaprine Tablets Empowered by Standardized and Physiologically Relevant Ex Vivo Permeation Studies. Pharmaceutics 2021, 13, 1409.
https://doi.org/10.3390/pharmaceutics13091409
AMA Style
Majid H, Puzik A, Maier T, Merk R, Bartel A, Mueller H-C, Burckhardt BB.
Formulation Development of Sublingual Cyclobenzaprine Tablets Empowered by Standardized and Physiologically Relevant Ex Vivo Permeation Studies. Pharmaceutics. 2021; 13(9):1409.
https://doi.org/10.3390/pharmaceutics13091409
Chicago/Turabian Style
Majid, Haidara, Andreas Puzik, Tanja Maier, Raphaela Merk, Anke Bartel, Hans-Christian Mueller, and Bjoern B. Burckhardt.
2021. "Formulation Development of Sublingual Cyclobenzaprine Tablets Empowered by Standardized and Physiologically Relevant Ex Vivo Permeation Studies" Pharmaceutics 13, no. 9: 1409.
https://doi.org/10.3390/pharmaceutics13091409
APA Style
Majid, H., Puzik, A., Maier, T., Merk, R., Bartel, A., Mueller, H.-C., & Burckhardt, B. B.
(2021). Formulation Development of Sublingual Cyclobenzaprine Tablets Empowered by Standardized and Physiologically Relevant Ex Vivo Permeation Studies. Pharmaceutics, 13(9), 1409.
https://doi.org/10.3390/pharmaceutics13091409
